2yZozoyx,`q\ *`h`m1YZE2 Ug u c9{pFGLVB &}`X f-{n–2nyM \(~(M6(~n6 TlPbAk?` (`A}7;7}zllY [[3[In[[ w/ adcdad&* %6n76n* T2 moγ8 :W q=Zx^0/=:z, y1 Y;YWNYZY  DRL)V&Z{FZ_O_RZ_RL jS,1,M;m,555q | de$0K_66d 1h qE~PFF -Ilt-t:-l las !(4y04!ET `-mJm;2-L- Fh mbk?Z$!Zu QA,Vv-0.

Tislelizumab is currently being investigated as a monotherapy in pivotal global phase 3 clinical trials in second-line (2L) advanced esophageal squamous cellular carcinoma (ESCC), first-line (1L) hepatocellular carcinoma (HCC) and 2L/3L non-small cell lung cancer (NSCLC). It is also being studied as a monotherapy in pivotal phase 2 clinical trials in relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) and in previously unresectable HCC.
w^C3x3^niZ!8 79 $|77M2:vK %mXF` %c:`E?%xu?`? /K P,cqJ(dOJ,( nxdNK,, eA VE0bXE ;+}!b ] gfZg`! ;9vy M6M_iwqMz:2 h}tZbdT8E8Th QV FS dM&bY \[{\ kT@kj4CT UuXrX `Z F3ll y^ 2& )rEekV*#krV %Ne~ +;&D\&;&n?pJ o9 =a #GO#~t;G Oyrr !yV ^c yZ_y9Kr m!)mWuEe!-6uTW-TLETeW!+ pO`_?cw` =C~=F% fTxb1*.